Title: Anti-PSMA labeled liposomes loaded with Actinium-225 for potential alpha-particle radiotherapy of tumor vasculature
Authors: BANDEKAR AmeyZHU CharlesJINDAL RohitBANERJEE Sangeeta RayPOMPER MartinBRUCHERTSEIFER FrankMORGENSTERN AlfredSOFOU Stavroula
Citation: Proceedings of the 8th Symposium on Targeted Alpha Therapy p. 47
Publisher: Oak Ridge National Laboratory
Publication Year: 2013
JRC N°: JRC82796
URI: https://register.ornl.gov/2013/TATS/index.shtml
http://publications.jrc.ec.europa.eu/repository/handle/JRC82796
Type: Articles in periodicals and books
Abstract: We study targeted liposomes loaded with the alpha-particle generator Actinium-225 (225Ac) to selectively kill prostate-specific-membrane-antigen-(PSMA)-expressing cells with the aim to evaluate their potential for targeted antivascular alpha-radiotherapy. This is a bottom-up design and the rationale for the chosen components is the following: The targeted moiety is PSMA which is unique to human tumor vasculature for several different types of primary human cancers. The therapeutic radionuclide, 225Ac, emits a total of four alpha-particles per decay providing highly lethal and localized irradiation of targeted cells with minimal exposure of surrounding healthy tissues. And, finally, the delivery carrier is a lipid-based nanocarrier (a liposome). Liposomes can be loaded with high radioactivities, and, in terms of toxicities, liposomes can be easily engineered (by altering their size and surface characteristics) to become rapidly cleared from circulation with the aim to shift the distribution of normal organ toxicities away from the kidneys (the dose limiting organ in the case of 225Ac-labeled antibodies) and toward the spleen and the liver.
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.